EP3268464A4 - Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration - Google Patents

Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration Download PDF

Info

Publication number
EP3268464A4
EP3268464A4 EP16769297.9A EP16769297A EP3268464A4 EP 3268464 A4 EP3268464 A4 EP 3268464A4 EP 16769297 A EP16769297 A EP 16769297A EP 3268464 A4 EP3268464 A4 EP 3268464A4
Authority
EP
European Patent Office
Prior art keywords
cancer
monitoring
response
methods
helper type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16769297.9A
Other languages
German (de)
French (fr)
Other versions
EP3268464A1 (en
Inventor
Gary K. Koski
Jashodeep DATTA
Brian J. Czerniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/020613 external-priority patent/WO2015139003A1/en
Priority claimed from US14/985,303 external-priority patent/US20160252511A1/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2016/020987 external-priority patent/WO2016153761A1/en
Publication of EP3268464A1 publication Critical patent/EP3268464A1/en
Publication of EP3268464A4 publication Critical patent/EP3268464A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16769297.9A 2015-03-13 2016-03-04 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration Withdrawn EP3268464A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2015/020613 WO2015139003A1 (en) 2014-03-14 2015-03-13 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/658,095 US20150323547A1 (en) 2014-03-14 2015-03-13 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/985,303 US20160252511A1 (en) 2014-03-14 2015-12-30 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
PCT/US2016/020987 WO2016153761A1 (en) 2015-03-13 2016-03-04 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

Publications (2)

Publication Number Publication Date
EP3268464A1 EP3268464A1 (en) 2018-01-17
EP3268464A4 true EP3268464A4 (en) 2018-08-08

Family

ID=60623921

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16769297.9A Withdrawn EP3268464A4 (en) 2015-03-13 2016-03-04 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

Country Status (1)

Country Link
EP (1) EP3268464A4 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015139003A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015139003A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATTA JASHODEEP ET AL: "Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration", ONCOIMMUNOLOGY, vol. 4, no. 10, 1 April 2015 (2015-04-01), XP002782236, ISSN: 2162-402X *
FRACOL MEGAN ET AL: "Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.", ANNALS OF SURGICAL ONCOLOGY, vol. 24, no. 2, 23 February 2017 (2017-02-23), pages 407 - 417, XP002782238, ISSN: 1534-4681 *
JASHODEEP DATTA ET AL: "Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer", BREAST CANCER RESEARCH, vol. 17, no. 1, 23 May 2015 (2015-05-23), pages 1 - 15, XP055358240, DOI: 10.1186/s13058-015-0584-1 *
See also references of WO2016153761A1 *
XU SHUWEN ET AL: "Abstract 4079: Reversal of immune evasion mediated by HER2 requires both humoral and cellular HER-2 targeted immune interventions", CANCER RESEARCH, vol. 74, no. 19, Suppl. S, October 2014 (2014-10-01), & 105TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); SAN DIEGO, CA, USA; APRIL 05 -09, 2014, XP002782237, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2014-4079 *

Also Published As

Publication number Publication date
EP3268464A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
EP3236903A4 (en) Methods and formulations for transdermal administration
EP3237003A4 (en) Nanoparticle compositions and methods for immunotherapy
EP3107576A4 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
EP3164114A4 (en) Purified therapeutic nanoparticles and preparation methods thereof
EP3119376A4 (en) Multi-size pill splitter and methods
EP3325990A4 (en) Gradiometer system and method
EP3155399A4 (en) Viscometer and methods for using the same
EP3129402A4 (en) Site-specific antibody-drug glycoconjugates and methods
EP3368546A4 (en) Sstr-targeted conjugates and particles and formulations thereof
EP3142705A4 (en) Polymer-flavonoid conjugate and uses thereof
EP3113798A4 (en) Methods and compositions for modifying the immune response
EP3105725A4 (en) Remittance system and method
EP3224781A4 (en) Transaction system and method
EP3232389A4 (en) Intelligent wearable device and non-contact payment method
EP3124071A4 (en) Connector and infusion set
EP3395188A4 (en) Soluble dietary fiber and preparation method thereof
EP3191091A4 (en) Dietary emulsion formulations and methods for using the same
EP3201526A4 (en) Illuminated garment system and method of using the same
GB201416293D0 (en) Methods and preparations
EP3185873A4 (en) Pharmaceutical composition and methods
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
EP3368163A4 (en) Mouthwash products and methods
EP3238758A4 (en) Hemodiafilter and hemodiafiltration device
EP3208767A4 (en) Appraisal system and appraisal method
EP3097420A4 (en) Methods and compositions for immune dis-inhibition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101ALI20180625BHEP

Ipc: A61K 35/12 20150101ALI20180625BHEP

Ipc: C12N 5/078 20100101AFI20180625BHEP

Ipc: A61K 38/20 20060101ALI20180625BHEP

Ipc: C12N 5/0784 20100101ALI20180625BHEP

Ipc: A61K 38/19 20060101ALI20180625BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180710

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101ALI20180703BHEP

Ipc: A61K 38/20 20060101ALI20180703BHEP

Ipc: C12N 5/0784 20100101ALI20180703BHEP

Ipc: A61K 38/19 20060101ALI20180703BHEP

Ipc: A61K 35/12 20150101ALI20180703BHEP

Ipc: C12N 5/078 20100101AFI20180703BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190801

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210824